If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-28. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Injury: A mild form of myositis can occur with hard exercise. A more severe form of muscle injury, called rhabdomyolysis, is also associated with myositis. This is a condition where an injury to the patient's muscles causes them to quickly break down. Medicines: A variety of different medicines can cause myositis. One of the most common types of drugs that can cause myositis are statins, which are used to lower cholesterol levels. One of the most common side effects of statin therapy is muscle pain which, more rarely, can lead to myositis. Infection: The most common infectious cause of myositis is viral infections, such as the common cold. Other viruses, such as COVID-19, are also shown to be a rare cause of myositis. Benign acute childhood myositis has been described in children after prodromal viral infections with different viral agents. Bacterial, parasitic, and fungal infections are other infectious causes of myositis. Inherited muscle disease: Many inherited myopathies may have secondary myositis, including calpainopathy, dysferlinopathy, facioscapulohumeral muscular dystrophy, dystrophinopathy, and LMNA-associated myopathy. Autoimmune: Autoimmune disease is an abnormal immune response to specific body protein or other biomolecular target, such as one of the muscles. The three main types of idiopathic myositis (known as inflammatory myopathies) that typically test positive for autoantibodies are dermatomyositis, polymyositis, and inclusion body myositis. Other autoimmune diseases, such as systemic lupus erythematosus, can also cause myositis-like symptoms.
Entourage Guimard: Square-Victoria–OACI station on the Montreal Metro in Canada has a genuine Guimard entrance made from parts of demolished Paris entrances (with map holder and "Métropolitain" sign and holder reproduced from the original molds). It was installed in 1967. During restoration in 2001–2002, it was found to have the last examples of the original glass light globes, which in Paris had been replaced with plastic for safety; one was returned to the RATP and the other placed on display in the Montreal Museum of Fine Arts. Bellas Artes station on the Mexico City Metro in Mexico has a Guimard entrance installed in 1998. Picoas station on the Lisbon Metro in Portugal has a Guimard entrance installed in 1995. Kievskaya station on the Moscow Metro in Russia has a Guimard entrance installed in 2007. Van Buren Street station on the Metra Electric District in Chicago had a Guimard entrance installed in 2001. An Entrance to the Paris Métropolitain: The National Gallery of Art in Washington, D.C., United States has a Guimard entrance in its sculpture garden, first shown at the gallery in a 2000–2001 exhibition on Art Nouveau and permanently installed in the garden in 2003. The Museum of Modern Art in New York City, United States has the archway consisting of the light stalks and "Métropolitain" sign from the Guimard entrance to Raspail station. The Dali Theater Museum in Figueres (Girona, Spain) has a pair of the light stalks from a Guimard Métro entrance, which are exhibited on the patio.
=== Stem cells === The precursor of the melanocyte is the melanoblast. In adults, stem cells are contained in the bulge area of the outer root sheath of hair follicles. When a hair is lost and the hair follicle regenerates, the stem cells are activated. These stem cells develop into both keratinocyte precursors and melanoblasts - and these melanoblasts supply both hair and skin (moving into the basal layer of the epidermis). There is additionally evidence that melanocyte stem cells are present in cutaneous nerves, with nerve signals causing these cells to differentiate into melanocytes for the skin.
Sources: en.wikipedia.org
On 9 May 2024, control Judge Juan Manuel Fernández López rejected Agüero's appeals against the prosecution's petition to take her to trial, and ordered that she stand trial on five counts of aggravated murder, as well as eight other counts of attempted murder. Along with Agüero, Judge Fernández López also ordered that 10 officials face trial at the same courtroom where Agüero will be tried. The trial against Brenda Agüero and the other ten defendants commenced on 6 January 2025. Agüero denied committing the crimes during her first testimony, saying that there is "no possibility that harming another person crosses my mind; much less a child." On 22 January, the mother of one of the babies who decompensated (a baby girl named Isabella) testified that she saw Agüero injecting her baby while the little girl was in the cradle. The woman said that the baby cried as Agüero injected her shortly before decompensating. On 30 January, medical professionals testified at the trial, saying that the babies did not die from a natural cause, and confirmed that the levels of potassium or insulin in their bodies were injected deliberately. On 4 February, a neonatal doctor testified that during her shift on 6 June 2022, when two healthy babies died without presumptive cause, she saw Brenda Agüero with a baby in her arms, and that Agüero told her that the baby "was not well". The baby later died from a serious case of bradycardia. The doctor also confirmed that the nature of the deaths of these healthy babies raised suspicions from the doctors who attempted to resuscitate them.
==== Non-Hodgkin lymphoma ==== Results from several studies indicate that, compared to other autoimmune diseases, Sjögren's disease is associated with a notably high incidence of non-Hodgkin lymphoma, a cancer of white blood cells. About 5% of patients with Sjögren's develop some form of lymphoid malignancy. Patients with severe cases are much more likely to develop lymphomas than patients with mild or moderate cases. The most common lymphomas are salivary extranodal marginal zone B cell lymphomas (MALT lymphomas in the salivary glands) and diffuse large B-cell lymphoma. Lymphomagenesis in primary Sjögren's disease patients is considered a multistep process, with the first step being chronic stimulation of autoimmune B cells, especially B-cells that produce rheumatoid factor at sites targeted by the disease. This increases the frequency of oncogenic mutation, leading to any dysfunction at checkpoints of autoimmune B-cell activation to transform into malignancy. A study's findings concluded that continuous stimulation of autoimmune B cells leads to subtle germinal abnormalities in genes having specific consequences in B cells, which underlie the susceptibility to lymphoma.
Plantar fasciitis is an often painful degenerative process of the plantar fascia. Calcaneal spur (heel spur) is a small calcified bone extension (osteophyte) located on the inferior aspect of the calcaneus or on the back of the heel at the insertion of the Achilles tendon. The condition is typically a response to plantar fasciitis over a period of time. Visualized on x-ray. It is mistaken for a sharp piece or horn of bone sticking out of the heel and instead is actually calcification of the plantar fascia, mistakenly thought to be a bone spur. It may also be related to ankylosing spondylitis, typically in children.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.